These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37332355)

  • 1. Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study.
    Li S; Wu X; Li N; Cao G; Wang J; Chen Y; Li S; He J; Wu J; Yang H; Lin K; Qiu C; Liu A; Zhou H; Adrian F; Schweizer L; Zhang W; Gu J; Zhang J
    Front Pharmacol; 2023; 14():1117293. PubMed ID: 37332355
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
    Wu X; Li N; Wang G; Liu W; Yu J; Cao G; Wang J; Chen Y; Ma J; Wu J; Yang H; Mao X; He J; Yu Y; Qiu C; Li N; Yao S; Feng H; Yan J; Zhang W; Zhang J
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0035021. PubMed ID: 33972256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody.
    Meng X; Wang P; Xiong Y; Wu Y; Lin X; Lu S; Li R; Zhao B; Liu J; Zeng S; Zeng L; Wu Y; Lu Y; Zhang J; Liu D; Wang S; Lu H
    Emerg Microbes Infect; 2021 Dec; 10(1):1638-1648. PubMed ID: 34346827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2.
    Zhang Q; Zhou R; Yang J; Dou C; Gan T; Liu F; Hu B; Song D; Lu C; Hu W
    Infect Dis Ther; 2022 Feb; 11(1):405-422. PubMed ID: 34878625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002-an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults.
    Chen G; Zhang Y; Wu K; Jin T; Peng C; Jiang Q; Tian W; Chen Z; Shen Z; Sheng G
    BMC Infect Dis; 2023 Jun; 23(1):437. PubMed ID: 37370000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study.
    Chen Q; Hu C; Yu H; Shen K; Assam PN; Gillen M; Liu Y; Dorinsky P
    Clin Ther; 2019 May; 41(5):897-909.e1. PubMed ID: 30982547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults.
    Prativadibhayankaram VS; Lee LS; Lye D; Xiaoying X; Nellore R; Pendharkar V; Hentze H; Guan S; Ayers BJ; Seah SGK; Chye H; Talib NSN; Kaliaperumal N; Ong WY; Wong ZX; Au VB; Alok A; Connolly JE; Boyd-Kirkup JD; Ingram PJ; Hanson BJ; Ethirajulu K; O'Connell D; Chan CEZ
    Infect Dis Ther; 2022 Oct; 11(5):1999-2015. PubMed ID: 36058990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers.
    Li X; Li B; Wang M; Fang M; Lou J; Liu J; Chen H; Ding Y
    BioDrugs; 2024 Mar; 38(2):313-321. PubMed ID: 38148466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
    Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers.
    Wu M; Zhang H; Li Q; Chen H; Fang M; Yang L; Ding Y
    Front Pharmacol; 2021; 12():794054. PubMed ID: 35310892
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults.
    Hao X; Zhang Z; Ma J; Cheng L; Ji Y; Liu Y; Zhao D; Zhang W; Li C; Yan L; Margolis D; Zhu Q; Zhang Y; Zhang F
    Front Pharmacol; 2022; 13():983505. PubMed ID: 36147329
    [No Abstract]   [Full Text] [Related]  

  • 17. LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA
    Cao G; Wang J; He J; Hu Y; Yang H; Que L; Gu X; Yu J; Wu X; Wu J; Fang W; He Q; Zhang J
    Front Pharmacol; 2023; 14():1111893. PubMed ID: 37081963
    [No Abstract]   [Full Text] [Related]  

  • 18. A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers.
    Wang J; Qi L; Liu L; Wang Z; Chen G; Wang Y; Liu X; Liu Y; Liu H; Tong Y; Liu C; Lei C; Wang X
    Front Pharmacol; 2019; 10():905. PubMed ID: 31474863
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
    Forte-Soto P; Albayaty M; Brooks D; Arends RH; Tillinghast J; Aksyuk AA; Bouquet J; Chen C; Gebre A; Kubiak RJ; Pilla Reddy V; Seegobin S; Streicher K; Templeton A; Esser MT
    J Infect Dis; 2023 May; 227(10):1153-1163. PubMed ID: 36683419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults.
    Schmidt P; Gong J; Narayan K; Gupta D; Engler F; Li Y; Copans A; Campanaro E
    Infect Dis Ther; 2023 May; 12(5):1365-1377. PubMed ID: 37185797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.